CASC3 and B-cell non-Hodgkin lymphoma: These observations lead to the evaluation of BTZ in combination with rituximab and/or systemic chemotherapy in patients with previously untreated or relapsed/refractory indolent or aggressive B-cell lymphoma [10–13].